It was previously reported that the activation of the PI3K/Akt/mTOR pathway has been observed in approximately 90% of HNSCC cases, making it a prominent target for treatments of HNSCC [35,36]. This evidence concerns the gene MTOR and head and neck squamous cell carcinoma.